Page 2 - Pharma Sector

USFDA pulls up Aurobindo Pharma for manufacturing lapses at API plant

The US Food and Drug Administration (USFDA) has issued a warning letter to Aurobindo Pharma for violating current good manufacturing practice norms at its Telangana-based plant.

Budget 2022: Pharma industry seeks enhanced funds for healthcare sector

The domestic pharmaceutical industry is expecting an increase in the overall fund allocation for the healthcare sector, focus on policies that encourage R&D activities and continuation of tax concessions on various drugs in the upcoming Union Budget. The industry is also seeking simplification of various processes in order to enhance ease of doing business for the private sector companies. "An increase in the budgetary allocation from the current 1.8 per cent of the GDP to 2.5-3 per cent, as envisaged in the National Health Policy 2017 along with a separate allocation for the bio-pharmaceutical sector R&D is imperative," Organisation of Pharmaceutical Producers of India (OPPI) President S Sridhar told PTI. The industry saw significant momentum over the past year, especially in ensuring access to COVID-19 vaccines and medicines and this year's Budget will be crucial to accelerate sectoral growth and access to innovative health solutions across various diseases and not COVID ...

Emcure Pharma's Rs 5,000-crore IPO to hit market early next month

Emcure Pharmaceuticals has received regulatory approvals for its draft red herring prospectus and will shortly be filing the RHP for the Rs 5,000-crore initial share sale, which will hit the market soon after the Budget, according to merchant banking sources. The IPO consists of a fresh issue of up to Rs 1,100 crore by the company, which will be used as growth capital, and an offer for sale by promoter shareholders -- founder, managing director & chief executive Satish Mehta who owns 41.92 per cent and by son Sunil Mehta who holds 6.13 per cent. Other promoter groups/persons who are participating in the OFS collectively own 33.55 per cent, and global private equity major Bain Capital owns 13.09 per cent in the Pune-headquartered pharma major which is the 12th largest player in the country. The sources, however, did not disclose how much each of the selling promoters will be offloading through the OFS. The company will utilize Rs 947 crore from the proceeds of the issue to ...

Covid may shift to endemic in 2022, says Moderna co-founder

World Health Organization officials have said it's too early to make that call as cases surge

InvaGen to continue to hold shares in Avenue Therapeutics: Cipla

In November 2018, Cipla had announced that InvaGen Pharmaceuticals Inc has entered into definitive agreements to acquire US-based speciality business firm Avenue Therapeutics for up to $215 million

Covid-19 & low base in 2020 boost anti-infectives growth, shows data

Antibiotics, antivirals spur drug category; chronic therapies post lower numbers

Aurobindo Pharma arm CuraTeQ expands scope of distribution pact with Orion

Aurobindo Pharma on Tuesday said its subsidiary CuraTeQ Biologics has expanded the scope of its marketing and distribution agreement with Orion Corporation (Orion)

Omicron spread: Pfizer seeks conditional EU authorisation for Covid-19 pill

The announcement comes as countries in much of the 27-nation bloc are reporting soaring numbers of infections

Swiss drugmaker Idorsia's insomnia medicine gets US FDA's approval

The drug, to be available under the brand name Quviviq, was approved in doses of 25 mg and 50 mg based on data from two late-stage trials

Alembic gets USFDA nod for generic drug to treat bacterial infections

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Doxycycline Hyclate delayed-release tablets

IT services, telecom, financials: Sectors analysts are betting on for 2022

With the withdrawal of easy and cheap money globally, fundamentals would come to fore, analysts suggest. Therefore, one needs to stay invested in the right quality of stocks, analysts suggest

Cadila Healthcare's US arm receives FDA nod to market Pimavanserin capsule

Cadila Healthcare on Friday said its US arm Zydus Pharmaceuticals (USA) Inc has received tentative approval from the US health regulator to market generic Pimavanserin capsules, indicated for treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The approval by the US Food & Drug Administration for the generic Pimavanserin capsules is for the strength of 34 mg, Cadila Healthcare said in a regulatory filing. "The drug will be manufactured at the group's formulation manufacturing facility at SEZ Ahmedabad," it said. The group now has 325 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04, it added.

Demand tonic to spur pharma growth in FY22: A CRISIL analysis

But exports to stay under the weather; credit outlook remains stable

Pharma firms to roll out anti-Covid pill as DCGI approves emergency use

Six other homegrown pharma companies announced rolling out their generic versions of the drug shortly

Cipla receives EUA for oral antiviral drug to treat mild-to-moderate Covid

Cipla will soon make Cipmolnu 200 mg capsules, which will be available at all leading pharmacies and Covid treatment centres across the country

Torrent Pharma recalls over 27,000 bottles of blood pressure drug in US

The affected lot has been produced in India and later the company has supplied to its US-based subsidiary for distribution in the US, the world's largest market for generic drugs

Centre working on policy to encourage research in pharma sector: Mandaviya

The central government is formulating a policy to encourage research in pharmaceutical sector for patented drugs, he said

Zydus gets orphan drug designation from USFDA for antimalarial compound

The orphan drug designation provides eligibility for certain development incentives

Sun Pharma Advanced Research Co signs licensing pact with Biomodifying

Biomodifying will also receive a percentage of payments received for sublicenses of the licensed IP

Without innovation Indian pharma cannot touch $130 bn by 2030: Industry

Sun Pharma says it eyes $1.5 bn from innovative products in 3-4 years